Skip to main content
SpringerLink
Log in

Symposium Genetic Factors Influencing Drug Action

  • Conference paper
Verhandlungen der Deutschen Gesellschaft für innere Medizin

Part of the book series: Verhandlungen der Deutschen Gesellschaft für innere Medizin ((VDGINNERE,volume 89))

  • 25 Accesses

Zusammenfassung

Several studies have established that there is a relationship between the therapeutic effect and plasma concentrations of tricyclic antidepressants (cf. Sjöqvist et al. 1980). For nortriptyline (NT) this relationship is curvilinear, i.e., there is a less favourable response both at low and high plasma levels compared to intermediate concentrations (200–600 nM). Side-effects are usually seen at levels above the therapeutic concentrations. The pronounced interindividual differences in plasma levels demonstrated for all tricyclic antidepressants are mainly due to a corresponding variability in the activity of the hepatic cytochrome P-450 system (loc. cit.). For NT the variation depends on the capacity of the liver to 10-hydroxylate the drug (Alexanderson 1973).

The studies reviewed here have been supported by grants from the Swedish Medical Research Council (3902) and the Karolinska Institute

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alexanderson B (1973) Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics — A study in twins. Eur J Clin Pharmacol 6: 44–53

    Article  PubMed  CAS  Google Scholar 

  • Alexanderson B, Price Evans DA, Sjöqvist F (1969) Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy. Br Med J 2: 764–768

    Article  Google Scholar 

  • Åsberg M, Price Evans DA, Sjöqvist F (1971) Genetic control of nortriptyline kinetics in man .A study of the relatives of propositi with high plasma concentrations. J Med Genet 8: 129–135

    Article  PubMed  Google Scholar 

  • Bertilsson L, Åberg-Wistedt A (1983) The debrisoquine hydroxylation test predicts plasma levels of desipramine. Br J Clin Pharmacol 15: 388–390

    PubMed  CAS  Google Scholar 

  • Bertilsson L, Mellström B, Sjöqvist F (1979) Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci 25: 1285–1292

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Bertilsson L, Säwe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective No-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    Article  PubMed  CAS  Google Scholar 

  • Inaba T, Vinks A, Otton SU, Kalow W (1983) Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther 33: 394–399

    Article  PubMed  CAS  Google Scholar 

  • Mahgoub A, Idle JR, Dring R, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586

    Article  PubMed  CAS  Google Scholar 

  • Mellström B, von Bahr C (1981) Demethylation and hydroxylation of amitriptyline, nortriptyline and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab Dispos 9: 565–568

    PubMed  Google Scholar 

  • Mellström B, Bertilsson L, Säwe J, Sjöqvist F (1983) Metabolism of amitriptyline — relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (in press)

    Google Scholar 

  • Mellström B, Bertilsson L, Säwe J, Schulz H-U, Sjöqvist F (1981) E- and Z-10-hydroxylation of nortriptyline — Relationship to polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 30: 189–193

    Article  PubMed  Google Scholar 

  • Mellström B, Bertilsson L, Träskman L, Rollins D, Åsberg M, Sjöqvist F (1979) Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. Pharmacology 19: 282–287

    Article  PubMed  Google Scholar 

  • Sjöqvist F, Bertilsson L, Åsberg M (1980) Monitoring tricyclic antidepressants. Ther Drug Monitoring 2: 85–93

    Article  Google Scholar 

  • Träskman L, Åsberg M, Bertilsson L, Cronholm B, Mellström B, Neckers L, Sjöqvist F, Thorén P, Tybring G (1979) Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther 26: 600–610

    PubMed  Google Scholar 

References

  1. Britt BA (1982) Malignant hyperthermia: A review. In: Milton AS (ed) Handbook of experimental pharmacology, vol 60. Springer, Berlin Heidelberg, pp 547–615

    Google Scholar 

  2. Denborough MA (1980) The pathopharmacology of malignant hyperpyrexia. Pharmacol Ther [B] 9: 357–365

    Article  CAS  Google Scholar 

  3. Gronert GA (1980) Malignant hyperthermia. Anesthesiology 53: 395–423

    Article  PubMed  CAS  Google Scholar 

  4. Schulte-Sasse U, Eberlein HJ (1981) Maligne Hyperthermic — eine jetzt beherrschbare, potentiell letale Narkosekomplikation. Dtsch Med Wochenschr 106: 1405–1408

    Article  PubMed  CAS  Google Scholar 

  5. Kalow W, Britt BA (1973) Drugs causing rigidity in malignant hyperthermia. Lancet 2: 390–391

    Article  PubMed  CAS  Google Scholar 

  6. Kalow W, Britt BA, Cahn F-Y (1979) Epidemiology and inheritance of malignant hyperthermia. In: Britt BA (ed) International anesthesiology clinics. Little Brown and Company, Boston, Massachusetts, pp 119–139

    Google Scholar 

  7. Gordon RA (1973) History of the syndrome of malignant hyperthermia. In: Gordon RA, Britt BA, Kalow W (eds) International symposium on malignant hyperthermia. Charles C. Thomas, Springfield, Illinois, pp 5–10

    Google Scholar 

  8. Kalow W, Britt BA, Terreau ME, Haist C (1970) Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 2: 895–898

    Article  PubMed  CAS  Google Scholar 

  9. Kalow W, Britt BA, Peters P (1978) Rapid simplified techniques for measuring caffeine contraction for patients with malignant hyperthermia. In: Aldrete JA, Britt BA (eds) Malignant hyperthermia. Grune & Stratton Inc., New York, pp 339–350

    Google Scholar 

  10. Kalow W, Britt BA, Richter A (1977) The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can Anaesth Soc J 24: 678–694

    Article  PubMed  CAS  Google Scholar 

  11. Ellis FR, Keaney NP, Harriman DGF, Sumner DW, Kyei-Mensah K, Tyrrell JH, Hargreaves JB, Parikh RK, Mulrooney PL (1972) Screening for malignant hyperpyrexia. Br Med J 3: 559–561

    Article  PubMed  CAS  Google Scholar 

  12. Moulds RFW, Denborough MA (1974) A study of the action of caffeine, halothane, potassium chloride and procaine on normal human skeletal muscle. Clin Exp Pharmacol Physiol 1: 197–209

    Article  PubMed  CAS  Google Scholar 

  13. McPherson E, Taylor CA Jr (1982) The genetics of malignant hyperthermia: Evidence for heterogeneity. Am J Med Genet 11: 273–285

    Article  PubMed  CAS  Google Scholar 

  14. Britt BA, Endrenyi L, Scott E, Frodis W (1980) Effect of temperature, time and fascicle size on the caffeine contracture test. Can Anaesth Soc J 27: 1–11

    Article  PubMed  CAS  Google Scholar 

  15. Denborough MA, Galloway GJ, Hopkinson KC (1982) Malignant hyperpyrexia and sudden infant death. Lancet 2: 1068

    Article  PubMed  CAS  Google Scholar 

  16. Mastaglia FL (1982) Adverse effects of drugs on muscle. Drugs 24: 304–321

    Article  PubMed  CAS  Google Scholar 

  17. Linter SPK, Thomas PR, Withington PS, Hall MG (1982) Suxamethonium associated hypertonicity and cardiac arrest in unsuspected pseudohypertrophic muscular dystrophy. Br J Aanesth 54: 1331–1332

    Article  CAS  Google Scholar 

  18. Lockridge O, LaDu BN (1982) Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. J Biol Chem 257: 12012–12018

    PubMed  CAS  Google Scholar 

  19. Massoulie J, Bon S (1982) The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Ann Rev Neurosci 5: 57–106

    Article  PubMed  CAS  Google Scholar 

  20. Brown SS, Kalow W, Pilz W, Whittaker M, Woronick CL (1981) The plasma cholinesterases: A new perspective. Adv Clin Chem 22: 1–123

    Article  PubMed  CAS  Google Scholar 

  21. Lockridge O (1982) Substance P hydrolysis by human serum cholinesterase. J Neurochem 39: 106–110

    Article  PubMed  CAS  Google Scholar 

  22. Viby-Mogensen J (1982) Cholinesterase and succinylcholine. Laegeforeningens forlag, Copenhagen

    Google Scholar 

  23. Whittaker M, Vickers MD (1970) Initial experiences with the cholinesterase research unit. Br J Anaesth 42: 1016–1020

    Article  PubMed  CAS  Google Scholar 

  24. Viby-Mogensen J, Hanel HK (1978) Prolonged apnoea after suxamethonium. An analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand 22: 371–380

    Article  PubMed  CAS  Google Scholar 

  25. Kalow W (1962) Pharmacogenetics. In: Heredity and the response to drugs. Saunders, Philadelphia

    Google Scholar 

  26. Lockridge O, LaDu BN (1978) Comparison of atypical and usual human serum cholinesterase. Purification, number of active sites, substrate affinity, and turnover number. J Biol Chem 253: 361–366

    PubMed  CAS  Google Scholar 

  27. Goedde HW, Agarwal DP, Benkmann H-G (1979) Pharmacogenetics of cholinesterase: New variants and suxamethonium sensitivity. Aerztl Lab 25: 219–224

    Google Scholar 

  28. Simpson NE, Elliott CR (1982) Cholinesterase activity towards succinyldithiocholine as a possible predictor of succinylcholine sensitivity in usual and intermediate cholinesterase phenotypes. Am J Hum Genet 34: 62A

    Google Scholar 

Literatur

  1. Scharer L, Smith JP (1969) Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 71: 1113–1120

    PubMed  CAS  Google Scholar 

  2. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB (1972) Isoniazidassoziated hepatitis. Am Rev Respir Dis 106: 357–365

    PubMed  CAS  Google Scholar 

  3. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epier GR (1975) Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69: 289–302

    PubMed  CAS  Google Scholar 

  4. Riska N (1976) L’hépatite chez les sujets des groupes traités par l’isoniazide et chez ceux d’un group témoin. Bull Int Union Tuberci 51: 203–208

    CAS  Google Scholar 

  5. NIH-Conference (1976) Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 84: 181–192

    Google Scholar 

  6. Maddrey DC, Boitnot JK (1973) Isoniazid hepatitis. Ann Intern Med 79: 1–12

    PubMed  CAS  Google Scholar 

  7. Mitchell JR, Long MW, Thorgeirsson UP (1975) Acetylation rates and monthly liver function tests during one Year of isoniazid preventive therapy. Chest 68: 181–190

    Article  PubMed  CAS  Google Scholar 

  8. Boenicke R, Reif W (1953) Enzymatische Inaktivierung von Isonicotinsäure Hydrazin im menschlichen und tierischen Organismus. Arch Exp Pathol Pharmacol 220: 321–333

    Google Scholar 

  9. Boenicke R, Lisboa BP (1957) Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen (Untersuchungen an eineiigen Zwillingen). Naturwissenschaften 44: 314

    Article  Google Scholar 

  10. Evans DAP, Manley KA, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2: 485–491

    Article  PubMed  CAS  Google Scholar 

  11. Evans DAP, White TA (1964) Human acetylation polymorphism. J Lab Clin Med 63: 394–403

    PubMed  CAS  Google Scholar 

  12. Perry HM Jr, Tan EM, Cordody S, Sahamato A (1970) Relationship of acetyltransferase activity to antinuclear antibodies and toxic symptoms on hypertensive patients treated hydralatine. J Lab Clin Med 76: 114–125

    PubMed  Google Scholar 

  13. Hahn BH, Sharp GC, Irvin WS, Kantor OS, Gardner CA, Babby MK, Perry HM, Osterland CK (1972) Immune responses to hydralazine and nuclear antigens in hydralazine induced lupus erythematosus. Ann Intern Med 76: 365–374

    PubMed  CAS  Google Scholar 

  14. Perry HM Jr (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54: 58–72

    Article  PubMed  Google Scholar 

  15. Irias JJ (1975) Hydralazine-induced lupus erythematosus-like syndrome. Am J Dis Child 129: 862–864

    PubMed  CAS  Google Scholar 

  16. Drajer DE, Reidenberg MM, Sevy RW (1974) N-acetylprocainamide. An active metabolite of procainamide. Proc Soc Exp Biol Med 146: 358–363

    Google Scholar 

  17. Henningsen NC, Cederberg A, Hanson A, Johansson BW (1975) Effects of long-time treatment with procainamide. Acta Med Scand 198: 475–482

    Article  PubMed  CAS  Google Scholar 

  18. Karlsson E, Molin L (1975) Polymorphic acetylation of procainamide in healthy subjects. Acta Med Scand 197: 299–302

    Article  PubMed  CAS  Google Scholar 

  19. Evans DAP, Davison K, Pratt RTC (1965) The influence of acetylators phenotype on the effects of treating depression with phenelzine. Clin Pharmacol Ther 6: 430–435

    PubMed  CAS  Google Scholar 

  20. Schroder H, Campbell DTS (1972) Absorption, metabolism and excution of Salicylazosulphapyridine in man. Clin Pharmacol Ther 13: 539–551

    PubMed  CAS  Google Scholar 

  21. Das KM, Eastwood MA, McManus JPA, Sircus W (1973) Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylater phenotype. N Engl J Med 289: 491–495

    Article  PubMed  CAS  Google Scholar 

  22. Ellard GA, Gammon PT, Helmy HS, Rees RJW (1972) Dapsone acetylation and the treatment of leprosy. Nature 239: 159–160

    Article  PubMed  CAS  Google Scholar 

  23. Persönliche Mitteilung (1976) Dr. Phyllis Edwards, Director, Tuberculosis Controll Division, Center for Disease Control. NIH-Conference. Ann Intern Med 84: 186

    Google Scholar 

  24. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow DJ, Keiser HR (1975) Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 18:70–79

    PubMed  CAS  Google Scholar 

  25. Smith J, Tyrell WF, Gow A, Allan GW, Lees AW (1972) Hepatotoxicity in rifampicin-isoniazid treatment patients related to their rate of isoniazid inactivation. Chest 61: 587–588

    Article  PubMed  CAS  Google Scholar 

  26. Van Scoy RE (1977) Antituberculosis agents. Mayo Clin Proc 52: 694–700

    PubMed  Google Scholar 

  27. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran III GB (1976) Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 193: 901–903

    Article  PubMed  CAS  Google Scholar 

  28. Snodgrass WR, Potter WZ, Timbrell JA, Jollow DJ, Mitchell JR (1974) Possible mechanisms of isoniazid-related hepatic injury. Clin Res 22: 323 A (Abstract)

    Google Scholar 

  29. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD (1980) Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 213: 364–369

    PubMed  CAS  Google Scholar 

  30. Timbrell JA (1979) The role of metabolism in the hepatotoxicity of isoniazid and iproniazid. Drug Metab Rev 10: 125–147

    Article  PubMed  CAS  Google Scholar 

  31. Timbrell JA (1979) Studies on the role of acetylhydrazine in isoniazid hepatotoxicity. Arch Toxicol (Berl) [Suppl] 2: 1–8

    Google Scholar 

  32. Dickinson DS, Bailey WC, Hirschowitz BI, Eidus K (1977) The effect of acetylation status on isoniazid hepatitis. Am Rev Respir Dis (Suppl) 115: 395

    Google Scholar 

  33. Singapore Tuberculosis Services/British Medical Research Council (1977) Controlled trial of intermittent regimes of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Am Rev Respir Dis 116: 807

    Google Scholar 

  34. Ellard GA, Gammon PT (1976) Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 4: 83–113

    Article  PubMed  CAS  Google Scholar 

  35. Timbrell JA, Wright JM, Baillie TA (1977) Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther 22: 602–608

    PubMed  CAS  Google Scholar 

  36. Lal S, Singhal SN, Burley DM, Crossley G (1972) Effect of rifampicin and isoniazid on liver function. Br Med J 1: 148–150

    Article  PubMed  CAS  Google Scholar 

  37. Sehm G, Urbanczik R (1974) Die Bedeutung der INH-Schnell- und Langsaminaktivierer für die Transaminasenanstiege bei der kombinierten IHN-RMP-Therapie. Prax Pneumol 28: 613–615

    PubMed  CAS  Google Scholar 

  38. Grönhagen-Riska C, Hellstrom PE, Fröseth B (1978) Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis. Am Rev Respir Dis 118: 461–466

    PubMed  Google Scholar 

  39. Musch E, Oldershausen HF v (1978) Klinik und Pathogenese der „INH-Hepatitis“. Therapiewoche 28: 3267–3276

    Google Scholar 

  40. Pessayre D, Bentutes M, Degott C, Nouel O, Miguet JP, Rueff B, Benhamou JM (1977) Isoniazid-rifampicin fulminant hepatitis: a possible consequence of the enhancement of isoniazid-hepatotoxicity by enzyme-induction. Gastroenterology 72: 284–289

    PubMed  CAS  Google Scholar 

  41. Blanchon P, Paillas I, Holler A, Grosseille J, Blanchon B, Blanchon F (1973) Foie et rifampicine. Poumon Coeur 29: 737–752

    Google Scholar 

  42. Plonteux G, Heusghem C, Ferdinande R, Lecoq A, Winandy A, Parmentier IC (1974) Détections des effects Hepatiques de l’association rifampicineisoniazide chez l’homme. Nouv Presse Med 23: 727–732

    Google Scholar 

  43. Lees AW (1970) Rifampicin toxicity. Report of meeting of British thoracic and tuberculosis association. Tubercle 51: 222–223

    Article  Google Scholar 

  44. Kuntz HD, Rausch V (1977) Hepatotoxische Nebenwirkungen von Rifampicin. Med Welt 28: 1940–1942

    PubMed  CAS  Google Scholar 

  45. Nebout T, Dhumeaux D, Berthelot P (1974) Ictères et rifampicine. Étude critique. Nouv Press Med 3: 733–736

    CAS  Google Scholar 

  46. Deck KA, Gehrhardt A, Klein HO, Ludes H (1976) Häufigkeit, Diagnose und Verlauf hepatotoxischer Nebenwirkungen von Rifampicin. Med Klin 71: 1836–1841

    PubMed  CAS  Google Scholar 

  47. Scheuer PJ, Sommerfield IA, Lal S, Sherlock S (1974) Rifampicin hepatitis. A clinical and histological study. Lancet 1: 421–425

    Article  PubMed  CAS  Google Scholar 

  48. Newman R, Doster BE, Murray FJ, Ferebee-Woolperts R (1974) Rifampicin in initial treatment of pulmonary tuberculosis. Am Rev Respir Dis 109: 216

    PubMed  CAS  Google Scholar 

  49. Lesobre R, Ruffino J, Teyssier L, Archard F, Bretfort G (1969) Les ictères au cours du traitemant par la rifampicine. Rev Tuberci Pneumol 33: 393

    CAS  Google Scholar 

  50. Engbaek HC, Olesen Larsen S, Rasmussen KN, Vergmann B (1973) Initial treatment of tuberculosis with streptomycin and isoniazid combined with either aminosalyl (PAS) or rifampicin. Scand J Respir Dis 54: 83

    PubMed  CAS  Google Scholar 

  51. Baron DN, Bell JL (1974) Serum enzyme changes in patients receiving antituberculosis therapy with rifampicin or p-amino salicytic acid plus isoniazid and streptomycin. Tubercle 55: 115

    Article  PubMed  CAS  Google Scholar 

  52. Marche I, Hugues FC, Graiseley B, Marche C (1970) L’hépatite provoquée par l’association de rifampicine et d’isoniazide. Rev Tuberci Pneumol 34: 1110–1119

    Google Scholar 

  53. Guillermand I (1970) Interferences hépatiques de la rifampicine. Rev Prat (Paris) 20: 2415–2433

    Google Scholar 

  54. Tracquet A, Savinel E, Devinder B, Duthoit A (1969) La rifampicine dans le traitemant de la tuberculose pulmonaire. Acta Tuberc Pneumol Belg 60: 529–544

    Google Scholar 

  55. Powel-Jackson PR, Tredger JM, Smith HM, Davis M, Williams R (1981) Isoniazid-induced hepatic damage: interactions of rifampicin and isoniazid. In: Davis M, Tredger JM, Williams R (eds) Drug reactions and the liver. Pitman Medical, London, pp 197–201

    Google Scholar 

  56. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripathy SP (1970) Sulphadimidine acetylation test for classification of patients as slow or rapid acetylators of isoniazid. Br Med J 3: 495–497

    Article  PubMed  CAS  Google Scholar 

  57. Kutt H, Verebely K, McDowell F (1968) Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs. Neurology 18: 706–710

    PubMed  CAS  Google Scholar 

  58. Ochs HR, Bodem G, Dengler HJ (1980) Einfluß einer tuberkulostatischen Therapie auf die Kinetik von Diazepam und Desmethyldiazepam. Verh Dtsch Ges Inn Med 86: 1240–1242

    CAS  Google Scholar 

  59. Sies H, Weigl K, Waydhas C (1979) Metabolic consequences of drug oxidation in perfused liver and in isolated hepatocytes from phenobarbital pretreated rats. In: Estabrook RW, Lindenlauf E (eds) The induction of drug metabolism: Symposium, Ashford Castle, Ireland. May 24.–27. 1978. Schattauer, Stuttgart New York, pp 383–400

    Google Scholar 

  60. Weigl K, Sies H (1977) Drug oxidation dependent on cytochrome-P-450 in isolated hepatocytes. The role of the tricarboxylates and the aminotransferases in NADPH supply. Eur J Biochem 77: 401–408

    Article  PubMed  CAS  Google Scholar 

  61. Inouye B, Uchinomi Y, Wachi T (1974) In vivo effect of rifampicin and its derivatives on energy transfer reactions in mitochondria. J Antibiot (Tokyo) 27: 192–198

    Article  CAS  Google Scholar 

  62. Pessayre D, Mazel P (1976) Induction and inhibition of hepatic drug metabolising enzymes by rifampicin. Biochem Pharmacol 25: 943–949

    Article  PubMed  CAS  Google Scholar 

  63. Hughes HB, Biehl JP, Jones AP, Schmidt LH (1954) Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberci Pulmonal Dis 70: 266–273

    CAS  Google Scholar 

  64. Olsen H, Morland J (1978) Br Med J 2:1260

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Badawy AA-B (1978) Tryptophan pyrrolase, the regulatory free haem and hepatic porphyrias. Early depletion of haem by clinical and experimental exacerbators of porphyrias. Biochem J 172: 487–494

    PubMed  CAS  Google Scholar 

  2. Badawy AA-B (1981) Evidence against involvement of cytochrome P-450 haem in the regulation of synthesis of mammalian liver 5-aminolaevulinate synthase. Biochem J 202: 807–808

    Google Scholar 

  3. Brennan MJW, Cantrill RC, Kramer S (1980) Effect of δ-amino-laevulinic acid on gaba receptor binding in synaptic plasman membranes. Int J Biochem 12: 833–835

    Article  PubMed  CAS  Google Scholar 

  4. Doss M (1978) Relationship between acute hepatic prophyrias due to genetic variability of primary enzyme defects and limiting function of uroporphyrinogen synthase. Int J Biochem 9: 911–916

    Article  PubMed  CAS  Google Scholar 

  5. Doss M (1982) Hepatic porphyrias: Pathobiochemical, diagnostic, and therapeutic implications. In: Popper H, Schaffner F (eds) Progress in liver diseases, vol VIL Grune & Stratton, New York, pp 573–597

    Google Scholar 

  6. Doss M (1982) Krankheiten und Störungen der Porphyrin- und Hämsynthese. In: Gross R, Schölmerich P (Hrsg) Lehrbuch der Inneren Medizin. Schattauer, Stuttgart New York, S 957–971

    Google Scholar 

  7. Doss M, Baumann H, Sixel F (1982) Alcohol in acute porphyria. Lancet 1: 1307

    Article  PubMed  CAS  Google Scholar 

  8. Doss M, Becker U, Peter HJ, Kaffarnik H (1981) Drug safety in porphyria: Risks of valproate and metoclopramide. Lancet 2: 91

    Article  PubMed  CAS  Google Scholar 

  9. Doss M, Verspohl F (1980) The “glucose effect” in acute hepatic porphyrias and in experimental porphyria. Klin Wochenschr 59: 727–735

    Article  Google Scholar 

  10. Giger U, Meyer UA (1981) Induction of δ-aminolevulinate synthase and cytochrom P-450 hemoproteins in hepatocyte culture. Effect of glucose and hormones. J Biol Chem 256: 11182–11190

    PubMed  CAS  Google Scholar 

  11. Goldberg A, Rimington C (1962) Diseases of porphyrin metabolism. C. C. Thomas, Pubi., Springfield, Ill.

    Google Scholar 

  12. Granick S (1966) The induction in vitro of the synthesis of δ-aminolevulinic acid synthetase in chemical porphyria: A response to certain drugs, sex hormones and foreign chemicals. J Biol Chem 241: 1350–1375

    Google Scholar 

  13. Healey JF, Bonkowsky HL, Sinclair PR, Sinclair JF (1981) Conversion of 5-aminolaevulinate into haem by liver homogenates. Comparison of rat and chick embryo. Biochem J 198: 595–604

    PubMed  CAS  Google Scholar 

  14. Kalow W (1962) Pharmacogenetics. Heredity and the response to drugs. W. B. Saunders Comp., Philadelphia London

    Google Scholar 

  15. Kikichi G, Hayshi N (1981) Regulation by heme of synthesis and intracellular enzyme translocation of δ-aminolevulinate synthase in the liver. Mol Cell Biochem 37: 27–41

    Article  Google Scholar 

  16. Marks GS, Krupa V, Murphy F, Taub H, Blattel RA (1975) Mechanisms of drug-induced porphyrin biosynthesis. An NY Acad Sci 244: 472–480

    Article  CAS  Google Scholar 

  17. Marks GS, Reich T, Wan JKS, Singer MA (1982) Investigation of the membrane-fluidizing properties of porphyrin-inducing drugs. Can J Physiol Pharmacol 60: 936–941

    Article  PubMed  CAS  Google Scholar 

  18. Matteis F de (1976) The experimental hepatic porphyrias: Their relevance to human hepatic porphyria. In: Doss M, Nawrocki P (eds) Porphyrins in human diseases — report of the discussions. Falk-Foundation, Freiburg/Br., pp 122–127

    Google Scholar 

  19. Matteis F de (1978) Hepatic porphyrias caused by 2-allyl-2-isopropyl-acetamide, 3,5-diethoxycarbonyl-l,4-dehydrocollidine, griseofulvin and related compounds. In: Matteis F de, Aldringe WN (eds) Heme and hemoproteins. Springer, Berlin Heidelberg New York, pp 129–155

    Google Scholar 

  20. Maxwell JD, Meyer UA (1978) Pharmacogenetics in the field of heme metabolism: Drug sensitivity in hereditary hepatic porphyria. In: Matteis F de, Aldringe WN (eds) Heme and hemoproteins. Springer, Berlin Heidelberg New York, pp 239–254

    Google Scholar 

  21. McColl KEL, Moore MR, Thompson MR, Goldberg A (1981) Treatment with haematin in acute hepatic porphyria. Q J Med (New Series L) 198: 161–174

    Google Scholar 

  22. Meyer UA, Strand LJ, Doss M, Ress AC, Marver HS (1972) Intermittent acute porphyria — demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med 286: 1277–1282

    Article  PubMed  CAS  Google Scholar 

  23. Moore MR (1980) International review of drugs in acute porphyria-1980. Int J Biochem 12: 1089–1097

    Article  PubMed  CAS  Google Scholar 

  24. Netter KJ (1968) Kompetitive Wechselwirkungen zwischen Arzneimitteln. Verh Dtsch Ges Inn Med 74: 783–795

    PubMed  CAS  Google Scholar 

  25. Pierach CA, Bossenmaier I, Cardinal R, Weimer M, Watson CJ (1980) Hematin therapy in porphyric attacks. Klin Wochenschr 58: 829–832

    Article  PubMed  CAS  Google Scholar 

  26. Sixel F, Doss M (1982) Östrogeninduzierte chronische hepatische Porphyrie (Porphyria cutanea tarda). Verh Dtsch Ges Inn Med 88: 1066–1069

    Google Scholar 

  27. Schmidt R, Schwartz S, Watson CF (1954) Porphyrin content of bone marrow and liver in various forms of porphyria. Arch Intern Med 93: 167–190

    Article  Google Scholar 

  28. Tschudy DP, Bonkowsky HL (1972) Experimental porphyria. Fed Proc 31: 147–159

    PubMed  CAS  Google Scholar 

  29. Wetterberg I (1976) Report on an international survey on safe and unsafe drugs in acute intermittent porphyria. In: Doss M, Nawrocki P (eds) Porphyrins in human diseases — Report of the discussions. Falk-Foundation, Freiburg/Br., pp 191–202

    Google Scholar 

  30. With TK (1976) A short history of porphyrins and porphyrias. In: Doss M, Nawrocki P (eds) Porphyrins in human diseases — report of the discussions. Falk-Foundation, Freiburg/Br., pp 289–308

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Clinical Pharmacology at the Karolinska Inst., Huddinge Hospital, Huddinge, Sweden

    L. Bertilsson, B. Mellström, J. Säwe & F. Sjöqvist

  2. Dept. of Biochemical and Experimental Pharmacology, St. Mary’s Hospital, Medical School, London, UK

    R. L. Smith

  3. Dept. of Pharmacology, Univ. of Toronto, Canada

    W. Kalow

  4. Med. Univ.-Klinik Venusberg, Bonn, Deutschland

    E. Musch, M. Eichelbaum, W. von Sassen, M. Castro-Parra, J. K. Wang & H. J. Dengler

  5. Abt. Klin. Biochemie, Fachbereich Humanmedizin, Univ. Marburg, Deutschland

    M. Doss

Authors
  1. L. Bertilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Mellström
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Säwe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Sjöqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. L. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Kalow
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Musch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Eichelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. von Sassen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Castro-Parra
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. K. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H. J. Dengler
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Doss
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kliniken der Landeshauptstadt Wiesbaden, Wiesbaden, D-6200, Deutschland

    Bernhard Schlegel

Rights and permissions

Reprints and permissions

Copyright information

© 1983 J. F. Bergmann Verlag, München

About this paper

Cite this paper

Bertilsson, L. et al. (1983). Symposium Genetic Factors Influencing Drug Action. In: Schlegel, B. (eds) Verhandlungen der Deutschen Gesellschaft für innere Medizin. Verhandlungen der Deutschen Gesellschaft für innere Medizin, vol 89. J.F. Bergmann-Verlag. https://doi.org/10.1007/978-3-642-85456-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85456-9_27

  • Publisher Name: J.F. Bergmann-Verlag

  • Print ISBN: 978-3-8070-0335-1

  • Online ISBN: 978-3-642-85456-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation